Herantis Pharma’s financial calendar and annual general meeting for 2024
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Finland |
|---|---|
| Lista | First North Finland |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Herantis Pharma Plc | Company Release | December 13, 2023 at 17:10:00 EET
Herantis Pharma Plc (“Herantis”), a clinical-stage biotechnology company developing disease-modifying therapies for Parkinson’s disease, hereby publishes the financial calendar for 2024.
Financial year 2023:
| Quiet period before 2H and FY 2023 report | February 6 – March 6, 2024 |
| 2H and FY 2023 report | March 6, 2024 |
| Annual report 2023 | March 27, 2024 |
Financial year 2024:
| Deadline for submission of proposal for AGM | February 23, 2024 |
| Annual General Meeting (AGM) | April 24, 2024 |
| Quiet period before 1H 2024 report | July 24 – August 22, 2024 |
| 1H 2024 report | August 22, 2024 |
The dates are subject to change.
For more information, please contact:
Julie Silber/Gabriela Urquilla
Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19
Email: ir@herantis.com
Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. It combines the compelling mechanism of action of CDNF with the convenience of subcutaneous administration. A Phase 1a clinical trial has demonstrated a good safety and tolerability profile, and efficient blood-brain barrier penetration of subcutaneously administered HER-096 in humans. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Company website: www.herantis.com